



Continuation of Substance of Interview including description of the general nature of what was discussed:

1. Amend Claim 1 as follows: Page 27 of the Claims, line 27, delete "C1-C6 hydroxyalkyl," ; Page 28 of the Claims, line 1, delete "HSCH2-,".
2. Amend Claim 7 as follows: Page 30 of the Claims, line 1, after the words "in a mammal", add ", for treatment of thrombosis or fibrinolytic impairment in a mammal, wherein the thrombosis or fibrinolytic impairment is associated with formation of atherosclerotic plaques, venous and arterial thrombosis, myocardial ischemia, atrial fibrillation, deep vein thrombosis, coagulation syndromes, pulmonary fibrosis, cerebral thrombosis, thromboembolic complications of surgery or peripheral arterial occlusion," (the remainder of Claim 7 is unchanged).
3. Amend Claim 13 as follows: Page 31 of the Claims, line 32, delete "A" and add "The" ; line 32, after the word "method", add "of Claim 7".
4. Cancel Claims 9-12 and 14-21, pp. 31-33 of the Claims.